Data Sheet (Cat.No.T38622)

TargetMol

Bcl-xL antagonist 2

Chemical Properties



CAS No. : 1235032-75-3

Formula: C21H16N4O3S2

Molecular Weight: 436.51

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Bcl-xL antagonist 2 is an effective and selective antagonist of Bcl-xL with an IC50 of 91 nM and a Ki of 65 nM. Bcl-xL antagonist 2 induces apoptosis in cancer cells and can be used in studies about chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Targets(IC50)	Apoptosis,Bcl-2 Family
In vivo	Bcl-xL antagonist 2 (1 mg/kg;i.v.) exhibits good PK profile with CL, Vss, t1/2 and F of 0.47 mL/min/kg, 0.16 L/kg, 6.0 h and 16% in rats[1].

Solubility Information

Solubility	DMSO: 50 mg/mL (114.54 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Corn Oil: 5 mg/mL (11.45 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2909 mL	11.4545 mL	22.909 mL
5 mM	0.4582 mL	2.2909 mL	4.5818 mL
10 mM	0.2291 mL	1.1454 mL	2.2909 mL
50 mM	0.0458 mL	0.2291 mL	0.4582 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Koehler MF, et al. Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL. ACS Med Chem Lett. 2014;5 (6):662-667.
Wang L, et al. Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor. ACS Med Chem Lett. 2020;11(10):1829-1836.